References
- Moodley S, Sanatani S, Potts JE, Sandor GG. Postnatal outcome in patients with fetal tachycardia. Pediatr Cardiol 2012 [Epub ahead of print].
- Maeno Y, Hirose A, Kanbe T, Hori D. Fetal arrhythmia: prenatal diagnosis and perinatal management. J Obstet Gynaecol Res 2009;35:623–629.
- Krishnan A, Pike JI, Donofrio MT. Prenatal evaluation and management of fetuses exposed to anti-SSA/Ro antibodies. Pediatr Cardiol 2012 [Epub ahead of print].
- Skog A, Wahren-Herlenius M, Sundström B, Bremme K, Sonesson SE. Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies. Pediatrics 2008;121:e803–e809.
- Lulic Jurjevic R, Podnar T, Vesel S. Diagnosis, clinical features, management, and post-natal follow-up of fetal tachycardias. Cardiol Young 2009;19:486–493.
- Zhou K, Hua Y, Zhu Q, Liu H, Yang S, Zhou R, Guo N. Transplacental digoxin therapy for fetal tachyarrhythmia with multiple evaluation systems. J Matern Fetal Neonatal Med 2011;24:1378–1383.
- Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 2011;32:896–903.
- Calabrò MP, Cerrito M, Luzza F, Oreto G. Supraventricular tachycardia in infants: epidemiology and clinical management. Curr Pharm Des 2008;14:723–728.
- Schlechte EA, Boramanand N, Funk M. Supraventricular tachycardia in the pediatric primary care setting: age-related presentation, diagnosis, and management. J Pediatr Health Care 2008;22:289–299.